Mouse bone marrow-derived mast cells undergo exocytosis, prostanoid generation, and cytokine expression in response to G protein-activating polybasic compounds after coculture with fibroblasts in the presence of c-kit ligand.
Polycationic mast cell activators, such as compound 48/80 and substance P, have been reported to activate connective tissue-type mast cells specifically by interacting directly with the Gi family of trimeric GTP-binding protein. We now demonstrate that mouse bone marrow-derived mast cells (BMMC) developed in IL-3, an immature mast cell population lacking responsiveness to the Gi-coupled polycationic mast cell activators, underwent maturation toward a connective tissue-type mast cells-like phenotype that responded to polycationic compounds after only 4 to 6 days of coculture with Swiss 3T3 fibroblasts in concert with recombinant soluble c-kit ligand (KL), whereas 3T3 or KL alone was insufficient to mediate this process. Under optimal conditions, cocultured BMMC released approximately 30% beta-hexosaminidase and generated approximately 1 ng of PGD2/10(6) cells within a few minutes in response to compound 48/80 or substance P. Furthermore, these cells expressed cytokines, such as IL-1beta and IL-6, and PG endoperoxide synthase-2 1 to 4 h after stimulation with compound 48/80 or substance P. All these responses were suppressed effectively by pertussis toxin, implicating functional Gi coupling. Regardless of the remarkable change in polycationic compound sensitivity, there was only a minimal change in the constitutive expression of Gi3 alpha after coculture. These results together with the observation that before coculture BMMC responded to thrombin through its Gi-coupled receptor suggest that the alteration in a certain step(s) distinct from the level of Gi3 alpha protein expression is important for the acquisition of responsiveness to the polycationic compounds by the synergistic action of KL and 3T3 fibroblast-derived factor. Several lines of evidence have revealed that 3T3-derived factor appears to differ from the known cytokines, prostanoids, and adhesion molecules and is a labile soluble substance.
Ogasawara
T
T
Department of Molecular Pharmacology, Meiji College of Pharmacy, Nozawa, Setagaya-ku, Tokyo, Japan.
Murakami
M
M
Suzuki-Nishimura
T
T
Uchida
M K
MK
Kudo
I
I
D016475:3T3 Cells / Q000378:metabolism*; D000818:Animals; D001854:Bone Marrow Cells; D002412:Cations / Q000494:pharmacology*; D018920:Coculture Techniques; D016207:Cytokines / Q000096:biosynthesis* / Q000187:drug effects; D005089:Exocytosis / Q000187:drug effects / Q000276:immunology*; D019204:GTP-Binding Proteins / Q000096:biosynthesis* / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008407:Mast Cells / Q000187:drug effects* / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D037342:Pertussis Toxin; D015230:Prostaglandin D2 / Q000096:biosynthesis; D011453:Prostaglandins / Q000096:biosynthesis*; D019089:Stem Cell Factor / Q000494:pharmacology*; D013373:Substance P / Q000494:pharmacology; D010566:Virulence Factors, Bordetella / Q000494:pharmacology; D003189:p-Methoxy-N-methylphenethylamine / Q000494:pharmacology
D002412:Cations; D016207:Cytokines; D011453:Prostaglandins; D019089:Stem Cell Factor; D010566:Virulence Factors, Bordetella; D013373:Substance P; D003189:p-Methoxy-N-methylphenethylamine; D037342:Pertussis Toxin; D019204:GTP-Binding Proteins; D015230:Prostaglandin D2